FASN and ovarian carcinoma: Our data are consistent with a recent study showing the platinum‐resistant ovarian cancer cells can be re‐sensitised to platinum treatment by targeting glutamine metabolism.60 Our study has shown that combining cisplatin treatment with FASN inhibition caused downregulation of glutamine metabolism/glutaminolysis and β‐oxidation, which then led to reduction in nucleotides and glutathione synthesis.